|Bid||94.50 x 800|
|Ask||117.00 x 800|
|Day's Range||113.08 - 115.09|
|52 Week Range||95.27 - 116.49|
|PE Ratio (TTM)||20.49|
|Earnings Date||Jul 24, 2018|
|Forward Dividend & Yield||2.00 (1.81%)|
|1y Target Est||116.71|
Physicians and health plan executives agreed healthcare has made little progress toward value-based care since last year – more than two-thirds (67 percent) of physicians and health plan executives said the U.S. still has a fee-for-service system. Fifty-seven percent of health plan executives said they now believe physicians do not have the tools to succeed under value-based care, up significantly from 45 percent in last year's study.
Per Quest Diagnostics (DGX), growing strength of partnerships with health care leaders and strategic acquisitions are creating growth prospects for the top and bottom-line growth.
SECAUCUS, N.J. , July 11, 2018 /PRNewswire/ -- Quest Diagnostics Incorporated (NYSE: DGX), the world's leading provider of diagnostic information services, announced that it will report second quarter ...
This could indicate that investors who seek to profit from falling equity prices are not currently targeting DGX. Over the last one-month, outflows of investor capital in ETFs holding DGX totaled $2.83 billion.
NEW YORK, June 27, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Coca-Cola ...
It's part of a broader $350 million fund to prevent and treat Alzheimer's.
Stock Research Monitor: PKI, PRAH, and PRPO LONDON, UK / ACCESSWIRE / June 26, 2018/ If you want a free Stock Review on DGX sign up now at www.wallstequities.com/registration . On Monday, benchmark US ...
In the month since Quest Diagnostics Inc (NYSE: DGX ) announced a strategic partnership with UnitedHealth Group Inc (NYSE: UNH ), the stock has garnered a slew of upgrades. The Rating Barclays analyst ...
SECAUCUS, N.J. and ORLANDO, Fla., June 23, 2018 /PRNewswire/ -- Employer wellness programs that combine laboratory and biometric screening with digital behavioral counseling can significantly reduce employees' risk of developing chronic conditions such as diabetes and cardiovascular disease, according to new research from Quest Diagnostics (DGX), the world's leading provider of diagnostic information services.
Quest Diagnostics (DGX) reveals both sides of the same coin, reflecting its bleak aspects plaguing the stock as well as projecting its brighter side to denote a near-term rebound.
Name change coincides with refreshed 2018 product release featuring integrated deep search and other capabilities from Ephesoft to help healthcare organizations improve patient care, drive operational ...
Analyst Donald Hooker upgraded Laboratory Corp. Consolidation within the lab testing space is likely to occur as a result of both UnitedHealth Group Inc (NYSE: UNH) and Aetna Inc (NYSE: AET) opening up their networks to include both Laboratory Corp. and Quest Diagnostics as in-network providers, Hooker said in a research report.
SECAUCUS, N.J., June 4, 2018 /PRNewswire/ -- Quest Diagnostics Incorporated (DGX), the world's leading provider of diagnostic information services, announced that it is scheduled to speak at the William Blair 38th Annual Growth Stock Conference in Chicago. Mark Guinan, Executive Vice President and CFO will discuss the company's vision, goals and two-point strategy to accelerate growth and drive operational excellence. Quest Diagnostics empowers people to take action to improve health outcomes. Derived from the world's largest database of clinical lab results, our diagnostic insights reveal new avenues to identify and treat disease, inspire healthy behaviors and improve health care management.
With Morgan Stanley calling clinical laboratory services market a safe haven, let's find out what's working in favor and against this burgeoning niche market.
Clinical Genomics Technologies Pty. Ltd., a Bridgewater, N.J.-based developer of diagnostic tools for colorectal cancer, has completed a $26 million funding round.
Clinical Genomics drives the commercialization of Colvera™, a liquid biopsy test service for colorectal cancer (CRC) recurrence and the focus of growing clinical evidence to support its use as the first widely adopted blood test for CRC screening. BRIDGEWATER, N.J., June 01, 2018 (GLOBE NEWSWIRE) -- Clinical Genomics Technologies Pty Ltd (CG), a leading provider of CRC testing solutions, has completed a $26 million financing. The proceeds from this financing will be used to commercialize Colvera, a liquid biopsy blood test, for earlier detection of recurrent CRC and to advance Colvera for use in CRC screening.
Barely a month-and-a-half after upgrading Quest Diagnostics Inc (NYSE: DGX ) to Equal-weight, Morgan Stanley turned incrementally positive on the shares. The Analyst Analyst Ricky Goldwasser upgraded shares ...
Both Quest Diagnostics and LabCorp lost exclusive contracts, but their stocks surged following the news. Analysts said the pair of announcements may indicate that the lab services didn't have to resort to rock-bottom pricing to hold onto their agreements. Losing exclusive contracts might normally seem like bad news, but shares of Quest Diagnostics DGX and LabCorp LH surged on Friday after the rival lab services firms announced new non-exclusive agreements with health insurers.
Two American lab companies, Quest Diagnostics and Clinical Pathology Laboratories, have processed cervical cancer screenings for women in Ireland. But a government review in 2014 found the labs mistakenly cleared more than 200 women there who were later diagnosed with cervical cancer. CBS News' Roxana Saberi spoke with two women who received settlements.
Quest Diagnostics CEO Steve Rusckowski sits down exclusively with CNBC’s Meg Tirrell at the Piper Jaffray Heartland Healthcare Summit to talk innovations in testing, improving the patient experience, and how technology is changing Quest’s business mode...